JSPR · Jasper Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Qiming U.S. Healthcare Fund II, L.P. 10% Owner | ▲ Buy | Open Market | 8,519,648 Shares held | 1/27/2023 | View profile |
| ROCHE HOLDING LTD 10% Owner | ▼ Sell | Open Market | 4,549,606 Shares held | 1/25/2023 | View profile |
| Howard I. Hoffen Director | ▲ Buy | Option Exercise | 2,300,000 Shares held | 9/24/2021 | View profile |
| Clifford Kenneth F | ▲ Buy | Option Exercise | 2,300,000 Shares held | 9/24/2021 | View profile |
| VENKATARAMAN BALAJI | ▲ Buy | Option Exercise | 2,300,000 Shares held | 9/24/2021 | View profile |
| Amplitude Healthcare Holdings LLC 10% Owner | ▲ Buy | Option Exercise | 2,300,000 Shares held | 9/24/2021 | View profile |
| Velan Capital Investment Management LP 10% Owner | ▲ Buy | Open Market | 1,188,500 Shares held | 2/8/2024 | View profile |
| Judith Anne Shizuru Director | ▲ Buy | Open Market | 156,901 Shares held | 9/22/2025 | View profile |
| Ron Martell President, CEO and Director | ▲ Buy | Open Market | 74,118 Shares held | 9/22/2025 | View profile |
| William Lis See Remarks | ▼ Sell | Open Market | 53,521 Shares held | 10/13/2023 | View profile |
| Thomas G. Wiggans Director | ▲ Buy | Open Market | 41,000 Shares held | 9/22/2025 | View profile |
| Nolet Chris Director | ▲ Buy | Grant | 32,500 Shares held | 10/12/2022 | View profile |
| Jeetinder Singh Mahal See Remarks | ▼ Sell | Open Market | 25,009 Shares held | 12/12/2024 | View profile |
| Lawrence Otto Klein Chief Executive Officer | ▲ Buy | Grant | 24,500 Shares held | 10/12/2022 | View profile |
| French Anna Louise Director | ▼ Sell | Open Market | 23,750 Shares held | 4/14/2023 | View profile |
| EMSTER KURT VON Director | ▼ Sell | Open Market | 21,175 Shares held | 4/13/2023 | View profile |
| Svetlana Lucas Director | ▲ Buy | Open Market | 20,000 Shares held | 9/22/2025 | View profile |
| Edwin Jonathan Tucker Chief Medical Officer | ▲ Buy | Grant | 400 Shares held | 6/7/2024 | View profile |
Transaction History
| Thomas G. Wiggans | ▲ Buy | Open Market | 41,000 | $100K | 9/22/2025 |
| Svetlana Lucas | ▲ Buy | Open Market | 20,000 | $49K | 9/22/2025 |
| Ron Martell | ▲ Buy | Open Market | 41,000 | $100K | 9/22/2025 |
| Judith Anne Shizuru | ▲ Buy | Open Market | 41,000 | $100K | 9/22/2025 |
| Jeetinder Singh Mahal | ▲ Buy | Option Exercise | 900 | $6K | 12/12/2024 |
| Jeetinder Singh Mahal | ▼ Sell | Open Market | 900 | $20K | 12/12/2024 |
| Jeetinder Singh Mahal | ▼ Sell | Open Market | 900 | $19K | 9/12/2024 |
| Jeetinder Singh Mahal | ▲ Buy | Option Exercise | 900 | $6K | 9/12/2024 |
| Jeetinder Singh Mahal | ▲ Buy | Option Exercise | 900 | $6K | 6/12/2024 |
| Jeetinder Singh Mahal | ▼ Sell | Open Market | 900 | $22K | 6/12/2024 |
| Edwin Jonathan Tucker | ▲ Buy | Grant | 400 | $2K | 6/7/2024 |
| Jeetinder Singh Mahal | ▲ Buy | Option Exercise | 900 | $6K | 3/12/2024 |
| Jeetinder Singh Mahal | ▼ Sell | Open Market | 900 | $24K | 3/12/2024 |
| Velan Capital Investment Management LP | ▲ Buy | Open Market | 350,000 | $4.5M | 2/8/2024 |
| Thomas G. Wiggans | ▲ Buy | Open Market | 10,000 | $6K | 11/28/2023 |
| Thomas G. Wiggans | ▲ Buy | Open Market | 10,000 | $6K | 11/21/2023 |
| Thomas G. Wiggans | ▲ Buy | Open Market | 10,000 | $6K | 11/20/2023 |
| Thomas G. Wiggans | ▲ Buy | Open Market | 10,000 | $6K | 11/17/2023 |
| Thomas G. Wiggans | ▲ Buy | Open Market | 10,000 | $6K | 11/16/2023 |
| William Lis | ▼ Sell | Open Market | 7,965 | $7K | 10/13/2023 |
| Ron Martell | ▼ Sell | Tax Withholding | 87,531 | $74K | 10/12/2023 |
| Jeetinder Singh Mahal | ▼ Sell | Tax Withholding | 37,126 | $32K | 10/12/2023 |
| Jeetinder Singh Mahal | ▲ Buy | Option Exercise | 9,000 | $6K | 6/13/2023 |
| Jeetinder Singh Mahal | ▼ Sell | Open Market | 9,000 | $15K | 6/13/2023 |
| French Anna Louise | ▼ Sell | Open Market | 7,000 | $10K | 4/14/2023 |
| EMSTER KURT VON | ▼ Sell | Open Market | 9,075 | $14K | 4/13/2023 |
| William Lis | ▼ Sell | Open Market | 8,500 | $12K | 4/13/2023 |
| Ron Martell | ▼ Sell | Tax Withholding | 87,531 | $128K | 4/12/2023 |
| Jeetinder Singh Mahal | ▼ Sell | Tax Withholding | 37,126 | $54K | 4/12/2023 |
| Qiming U.S. Healthcare Fund II, L.P. | ▲ Buy | Open Market | 2,666,666 | $4.0M | 1/27/2023 |
| ROCHE HOLDING LTD | ▼ Sell | Open Market | 75,000 | $142K | 1/25/2023 |
| Lawrence Otto Klein | ▲ Buy | Grant | 24,500 | $0 | 10/12/2022 |
| EMSTER KURT VON | ▲ Buy | Grant | 30,250 | $0 | 10/12/2022 |
| Jeetinder Singh Mahal | ▲ Buy | Grant | 214,722 | $0 | 10/12/2022 |
| William Lis | ▲ Buy | Grant | 29,500 | $0 | 10/12/2022 |
| French Anna Louise | ▲ Buy | Grant | 30,750 | $0 | 10/12/2022 |
| Nolet Chris | ▲ Buy | Grant | 32,500 | $0 | 10/12/2022 |
| Judith Anne Shizuru | ▲ Buy | Grant | 29,500 | $0 | 10/12/2022 |
| Ron Martell | ▲ Buy | Grant | 506,250 | $0 | 10/12/2022 |
| William Lis | ▼ Sell | Open Market | 24,743 | $51K | 6/27/2022 |
| William Lis | ▼ Sell | Open Market | 24,743 | $50K | 6/24/2022 |
| William Lis | ▲ Buy | Grant | 89,972 | $0 | 3/21/2022 |
| Clifford Kenneth F | ▲ Buy | Option Exercise | 2,300,000 | — | 9/24/2021 |
| Howard I. Hoffen | ▲ Buy | Option Exercise | 2,300,000 | — | 9/24/2021 |
| VENKATARAMAN BALAJI | ▲ Buy | Option Exercise | 2,300,000 | — | 9/24/2021 |
| Amplitude Healthcare Holdings LLC | ▲ Buy | Option Exercise | 2,300,000 | — | 9/24/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Jasper Therapeutics Names Interim CFO
Jasper Therapeutics announced that Herb Cross will resign as Chief Financial Officer effective October 9, 2026. Jeet Mahal has been appointed as the interim Principal Financial Officer to take over the role. This leadership change occurs while the stock trades well below its 52-week high and near recent support levels.
Jasper Therapeutics Names Interim CFO. Jasper Therapeutics announced that Herb Cross will resign as Chief Financial Officer effective October 9, 2026. Jeet Mahal has been appointed as the interim Principal Financial Officer to take over the role. This leadership change occurs while the stock trades well below its 52-week high and near recent support levels.